Regenicin Inc.
Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of hea… Read more
Regenicin Inc. (RGIN) - Total Assets
Latest total assets as of March 2023: $11.86 Million USD
Based on the latest financial reports, Regenicin Inc. (RGIN) holds total assets worth $11.86 Million USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Regenicin Inc. - Total Assets Trend (2007–2022)
This chart illustrates how Regenicin Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Regenicin Inc. - Asset Composition Analysis
Current Asset Composition (September 2022)
Regenicin Inc.'s total assets of $11.86 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2022)
This chart illustrates how Regenicin Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regenicin Inc.'s current assets represent 100.0% of total assets in 2022, unchanged from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 94.0% of total assets in 2022, up from 89.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Regenicin Inc. Competitors by Total Assets
Key competitors of Regenicin Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Regenicin Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Regenicin Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Regenicin Inc. is currently not profitable relative to its asset base.
Regenicin Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 0.00 | 0.01 |
| Quick Ratio | 0.66 | 0.00 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.21 Million | $ -5.28 Million | $ -3.07 Million |
Regenicin Inc. - Advanced Valuation Insights
This section examines the relationship between Regenicin Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | 236.2% |
| Total Assets | $15.49K |
| Market Capitalization | $12.56K USD |
Valuation Analysis
Near Book Valuation: The market values Regenicin Inc.'s assets close to their book value ( 0.81x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Regenicin Inc.'s assets grew by 236.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Regenicin Inc. (2007–2022)
The table below shows the annual total assets of Regenicin Inc. from 2007 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-09-30 | $15.49K | +236.17% |
| 2021-09-30 | $4.61K | +11.30% |
| 2020-09-30 | $4.14K | -22.09% |
| 2019-09-30 | $5.32K | -90.58% |
| 2018-09-30 | $56.43K | -35.72% |
| 2017-09-30 | $87.79K | -75.60% |
| 2016-09-30 | $359.83K | -75.70% |
| 2015-09-30 | $1.48 Million | -48.70% |
| 2014-09-30 | $2.89 Million | +2896.27% |
| 2013-09-30 | $96.33K | -96.89% |
| 2012-09-30 | $3.10 Million | +0.34% |
| 2011-09-30 | $3.09 Million | +1.56% |
| 2010-09-30 | $3.04 Million | +7689.83% |
| 2007-09-30 | $39.00K | -- |